WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in...
Repligen (RGEN) Shares Skyrocket, What You Need To Know
Repligen’s (NASDAQ:RGEN) Q1 CY2026 Sales Beat Estimates
First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year Reiterating...
Barchart Research What to Expect from RGEN Earnings RGEN Generated May 4, 2026 Current Price $118.21 EPS Estimate $$0.38 Consensus Rating Strong Buy Average Move 6.06% Repligen's Margin Recovery Narrative...
Repligen (RGEN) Q1 Earnings Report Preview: What To Look For
Why Repligen (RGEN) Shares Are Plunging Today
WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The...
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know